cannabi
hope
for
drug
firm
a
prescript
cannabi
drug
made
by
uk
biotech
firm
gw
pharmaceut
is
set
to
be
approv
in
canada
the
drug
is
use
to
treat
the
central
nervou
system
and
allevi
the
symptom
of
multipl
sclerosi
m
a
few
week
ago
share
in
gw
pharma
lost
a
third
of
their
valu
after
uk
regul
said
they
want
more
evid
about
the
drug
benefit
but
now
canadian
author
have
said
the
sativex
drug
will
be
consid
for
approv
approxim
peopl
in
canada
have
been
diagnos
with
m
and
peopl
are
suffer
from
the
condit
in
the
uk
mani
patient
alreadi
smoke
cannabi
to
reliev
their
symptom
now
gw
pharma
sativex
mouth
spray
could
be
legal
avail
to
m
suffer
in
canada
within
the
next
few
month
thi
will
be
the
first
time
a
cannabisbas
drug
ha
been
approv
anywher
in
the
world
repres
a
landmark
for
gw
pharma
and
for
patient
with
m
final
approv
in
canada
should
now
be
littl
more
than
a
formal
analyst
said
and
the
compani
expect
full
approv
for
sativex
earli
in
we
are
delight
to
receiv
thi
qualifi
notic
from
health
canada
and
look
forward
to
receiv
regulatori
approv
for
sativex
in
canada
in
the
earli
part
of
said
gw
pharma
execut
chairman
dr
geoffrey
guy
the
uk
govern
grant
gw
pharma
a
licenc
to
grow
the
cannabi
plant
for
medic
research
purpos
satifex
consist
of
a
cannabi
extract
contain
tetrahydrocannabinol
and
cannabidiol
a
cocktail
that
ha
also
prove
effect
in
treat
patient
with
arthriti
thousand
of
plant
are
grown
at
a
secret
locat
somewher
in
the
english
countrysid
despit
hope
of
regulatori
approv
last
year
a
seri
of
delay
ha
put
back
sativex
launch
in
the
uk
the
latest
news
sent
share
in
gw
pharma
up
p
or
to
p
